 Connection
Prasad Padala to Apathy
This is a "connection" page, showing publications Prasad Padala has written about Apathy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.385 |
|
|
|
-
Padala PR, Padala KP, Majagi AS, Garner KK, Dennis RA, Sullivan DH. Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study. Medicine (Baltimore). 2020 Aug 14; 99(33):e21497.
Score: 0.705
-
Padala PR, Padala KP, Samant RS, James GA. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease. Int Psychogeriatr. 2020 04; 32(4):539-540.
Score: 0.680
-
Padala PR, Boozer EM, Lensing SY, Parkes CM, Hunter CR, Dennis RA, Caceda R, Padala KP. Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study. J Alzheimers Dis. 2020; 77(4):1483-1493.
Score: 0.675
-
Padala PR, Dennis RA, Padala KP. Addressing Possible Effects of Sleep Apnea in a Study of Methylphenidate for Apathy in Alzheimer's Disease: Response to Kolla and Mansukhani. Am J Psychiatry. 2018 08 01; 175(8):792-793.
Score: 0.612
-
Padala PR, Padala KP, Lensing SY, Jackson AN, Hunter CR, Parkes CM, Dennis RA, Bopp MM, Caceda R, Mennemeier MS, Roberson PK, Sullivan DH. Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. Psychiatry Res. 2018 03; 261:312-318.
Score: 0.588
-
Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2018 02 01; 175(2):159-168.
Score: 0.576
-
Padala PR, Padala KP, Sullivan DH, Reynolds DW, Desouza CV, Potter JF, Burke WJ. Improvement of glycemic control using methylphenidate treatment of apathy: a preliminary report. J Am Geriatr Soc. 2012 Jul; 60(7):1383-4.
Score: 0.401
-
Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH. Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother. 2012 Mar; 46(3):e8.
Score: 0.391
-
Zeng L, Perin J, Gross AL, Shade D, Lanct?t KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). Int J Geriatr Psychiatry. 2024 Jun; 39(6):e6108.
Score: 0.229
-
Lanct?t KL, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg PB, Shade D, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Padala KP, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. Am J Geriatr Psychiatry. 2023 12; 31(12):1077-1087.
Score: 0.214
-
Lanct?t KL, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer RW, Vieira D, Coulibaly H, Rosenberg PB, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). Int Psychogeriatr. 2023 11; 35(11):664-672.
Score: 0.212
-
Mintzer J, Lanct?t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, Padala PR, Brawman-Mintzer O, Porsteinsson AP, Lerner AJ, Craft S, Levey AI, Burke W, Perin J, Shade D. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021 11 01; 78(11):1324-1332.
Score: 0.192
-
Mortby ME, Adler L, Ag?era-Ortiz L, Bateman DR, Brodaty H, Cantillon M, Geda YE, Ismail Z, Lanct?t KL, Marshall GA, Padala PR, Politis A, Rosenberg PB, Siarkos K, Sultzer DL, Theleritis C. Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. Am J Geriatr Psychiatry. 2022 02; 30(2):119-147.
Score: 0.187
-
Lanct?t KL, Scherer RW, Li A, Vieira D, Coulibaly H, Rosenberg PB, Herrmann N, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Burke WJ, Mintzer JE. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. Am J Geriatr Psychiatry. 2021 01; 29(1):81-89.
Score: 0.174
-
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanct?t KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. Am J Geriatr Psychiatry. 2021 01; 29(1):51-62.
Score: 0.173
-
Scherer RW, Drye L, Mintzer J, Lanct?t K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018 Jan 18; 19(1):46.
Score: 0.147
-
Lanct?t KL, Ag?era-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, Marshall GA, Mortby ME, Onyike CU, Padala PR, Politis AM, Rosenberg PB, Siegel E, Sultzer DL, Abraham EH. Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimers Dement. 2017 01; 13(1):84-100.
Score: 0.132
-
Desouza CV, Padala PR, Haynatzki G, Anzures P, Demasi C, Shivaswamy V. Role of apathy in the effectiveness of weight management programmes. Diabetes Obes Metab. 2012 May; 14(5):419-23.
Score: 0.097
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|